We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 42.19 | 50.80 | 49.595 | 48.97 | 49.48 | 1,113,911 | 05:00:11 |
From May 2019 to May 2024
By Alberto Delclaux
Sanofi SA (SAN.FR) said Thursday it had finalized negotiations to sell its European generics business Zentiva to Advent International Corp. for 1.9 billion euros ($2.2 billion).
The two companies have signed a share-purchase agreement and the operation is expected to close in the fourth quarter, subject to regulatory approvals, Sanofi said.
Write to Alberto Delclaux at alberto.delclaux@dowjones.com
(END) Dow Jones Newswires
June 28, 2018 01:30 ET (05:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
